Parker Waichman LLP Files Lawsuit Alleging Actos Caused Bladder Cancer in North Carolina Man

Share Article

Parker Waichman LLP has filed a lawsuit on behalf of a North Carolina man who developed bladder cancer, allegedly due to using Actos (pioglitazone), a Type 2 diabetes medication. According to the U.S. Food and Drug Administration (FDA), using Actos for more than one year may be associated with an increased risk of bladder cancer.

News Image
The lawsuit alleges that the Defendants knew Actos could increase the risk of bladder cancer but did not warn the Plaintiff or the public.

Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed a lawsuit alleging that Actos caused bladder cancer in a North Carolina man. The lawsuit was filed on November 16, 2012 in the U.S. District Court for the Western District of Louisiana, Lafayette Division (Case No. 6:12-cv-2902) where it is one of many cases pending in the multidistrict litigation known as In Re: Actos (Pioglitazone) Products Liability Litigation (MDL No. 6:11-md-2299). Jerrold S. Parker, founder partner of Parker Waichman, serves on the Plaintiffs’ Steering Committee. Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals USA, Inc. f/k/a Takeda Pharmaceuticals North America. Inc., Takeda Pharmaceutical Company Limited and Eli Lilly and Company have been named as Defendants.

According to the Complaint, the Plaintiff began taking Actos in 2002. Thereafter, he developed bladder cancer, allegedly due to using the medication. The lawsuit alleges that the Plaintiff suffered a number of damages as a result of using Actos, including severe mental and physical pain and suffering, permanent injuries, emotional distress and economic loss. The suit is also alleging loss of consortium on behalf of the Plaintiff’s wife.

The lawsuit alleges that the Defendants knew Actos could increase the risk of bladder cancer but did not warn the Plaintiff or the public. According to the lawsuit, the Plaintiff would not have taken Actos if he were aware of the risks.

The U.S. Food and Drug Administration (FDA) has updated the warning label on Actos, cautioning that use of the drug for more than one year may be associated with a higher risk of bladder cancer. According to a study published in the Journal of the National Cancer Institute, using Actos and other medications in the thiazolidinedione class could raise the risk of bladder cancer when used as a long-term therapy. In July 2012, the Canadian Medical Association Journal published a study showing that Actos is linked to a 22 percent increased risk of bladder cancer.

Parker Waichman LLP continues to offer free legal consultations to victims of Actos injuries, including bladder cancer, heart problems, and eye injuries. If you or a loved one were diagnosed with bladder cancer after taking Actos, please contact their office by visiting yourlawyer.com. Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).

Contact:
Parker Waichman LLP
Gary Falkowitz, Managing Attorney
(800) LAW-INFO
(800) 529-4636
http://www.yourlawyer.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Gary Falkowitz
Parker Waichman LLP
1-800-529-4636
Email >
Follow us on
Visit website